ORTX Orchard Rx ADS

Orchard Therapeutics to Present at Investor Conferences in March

Orchard Therapeutics to Present at Investor Conferences in March

BOSTON and LONDON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global leader in gene therapy, today announced that members of the management team will present at the following investor conferences in March:

  • Cowen 40th Annual Healthcare Conference on March 4, 2020, at 8:00 AM ET in Boston, MA
  • Oppenheimer 30th Annual Healthcare Conference on March 18, 2020, at 10:55 AM ET in New York City, NY 

Live webcasts of the presentations will be available under "News & Events" in the Investors & Media section of the company's website at . Webcast replays will be archived on the Orchard website following the presentation.

About Orchard

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically-modified blood stem cells and seeks to permanently correct the underlying cause of disease in a single administration. The company has one of the deepest gene therapy pipelines in the industry and is advancing seven clinical-stage programs across multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist, including inherited neurometabolic disorders, primary immune deficiencies and blood disorders.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit -tx.com, and follow us on Twitter and LinkedIn.

Contacts

Investors

Renee Leck

Director, Investor Relations



Media

Molly Cameron

Manager, Corporate Communications



EN
26/02/2020

Underlying

ORTXOrchard Rx ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orchard Rx ADS

 PRESS RELEASE
Free
ORTX ORCHARD RX ADS

Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024

Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024 Eight presentations showcase the broad applicability of HSC gene therapy to address rare neurometabolic diseases and beyond TOKYO, LONDON and BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced four oral and four poster presentations from across its hematopoietic stem cell (HSC) gene therapy platform will be featured at the 27th Annual Meeting of the American Society ...

May 7, 2024 1 EN
 PRESS RELEASE
Free
ORTX ORCHARD RX ADS

Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby ...

Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, has been to the inaugural 2024 TIME100 Health, an annual list recognizing the impact, innovation, and achievement of the world’s most influential individuals in health this yea...

May 3, 2024 1 EN
 PRESS RELEASE
Free
ORTX ORCHARD RX ADS

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidars...

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy Five specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families Orchard Assist patient services program to provide individualized support throughout the treatment process Lenmeldy wholesale acquisition cost of $4.25 million for one-time treatment reflects its clinical, economic and societal value Innovative outcomes- and value-based agreements...

March 20, 2024 1 EN
 PRESS RELEASE
Free
ORTX ORCHARD RX ADS

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene ...

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S. One-time treatment with Lenmeldy has shown the potential to restore enzymatic function to stop or slow disease progression, with up to 12 years of follow-up (median 6.76 years) TOKYO and LONDON and BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced the U....

March 18, 2024 1 EN
 PRESS RELEASE
Free
ORTX ORCHARD RX ADS

Orchard Therapeutics Announces First Patient Randomized in Registratio...

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S. and Europe TOKYO, LONDON and BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients ar...

February 5, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch